{"id":8888,"date":"2024-06-27T13:28:57","date_gmt":"2024-06-27T13:28:57","guid":{"rendered":"https:\/\/www.lupuscanada.org\/?p=8888"},"modified":"2024-06-28T14:04:07","modified_gmt":"2024-06-28T14:04:07","slug":"le-belimumab-benlysta-est-maintenant-inscrit-en-saskatchewan-et-en-nouvelle-ecosse-pour-le-traitement-du-lupus-et-de-la-nephrite-lupique","status":"publish","type":"post","link":"https:\/\/www.lupuscanada.org\/fr\/le-belimumab-benlysta-est-maintenant-inscrit-en-saskatchewan-et-en-nouvelle-ecosse-pour-le-traitement-du-lupus-et-de-la-nephrite-lupique\/","title":{"rendered":"Le belimumab (Benlysta) est maintenant approuv\u00e9 en Saskatchewan, en Nouvelle-\u00c9cosse et au Nouveau-Brunswick pour le traitement de la n\u00e9phrite lupique"},"content":{"rendered":"<p>[et_pb_section fb_built=\u00a0\u00bb1&Prime; _builder_version=\u00a0\u00bb4.25.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb da_disable_devices=\u00a0\u00bboff|off|off\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb da_is_popup=\u00a0\u00bboff\u00a0\u00bb da_exit_intent=\u00a0\u00bboff\u00a0\u00bb da_has_close=\u00a0\u00bbon\u00a0\u00bb da_alt_close=\u00a0\u00bboff\u00a0\u00bb da_dark_close=\u00a0\u00bboff\u00a0\u00bb da_not_modal=\u00a0\u00bbon\u00a0\u00bb da_is_singular=\u00a0\u00bboff\u00a0\u00bb da_with_loader=\u00a0\u00bboff\u00a0\u00bb da_has_shadow=\u00a0\u00bbon\u00a0\u00bb][et_pb_row _builder_version=\u00a0\u00bb4.16&Prime; background_size=\u00a0\u00bbinitial\u00a0\u00bb background_position=\u00a0\u00bbtop_left\u00a0\u00bb background_repeat=\u00a0\u00bbrepeat\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.16&Prime; custom_padding=\u00a0\u00bb|||\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb custom_padding__hover=\u00a0\u00bb|||\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.25.0&Prime; background_size=\u00a0\u00bbinitial\u00a0\u00bb background_position=\u00a0\u00bbtop_left\u00a0\u00bb background_repeat=\u00a0\u00bbrepeat\u00a0\u00bb custom_margin=\u00a0\u00bb-18px||||false|false\u00a0\u00bb hover_enabled=\u00a0\u00bb0&Prime; global_colors_info=\u00a0\u00bb{}\u00a0\u00bb sticky_enabled=\u00a0\u00bb0&Prime;]<!-- divi:paragraph --><\/p>\n<p>Nous sommes heureux d\u2019annoncer que le belimumab (Benlysta), un m\u00e9dicament d\u2019ordonnance utilis\u00e9 pour traiter les adultes atteints d\u2019inflammation r\u00e9nale li\u00e9e au lupus (n\u00e9phrite lupique active), a \u00e9t\u00e9 inclus dans la prestation du statut de drogue d\u2019exception (EDS) des listes de m\u00e9dicaments de la Saskatchewan et de la Nouvelle-\u00c9cosse \u00e0 compter du <strong>1er mai 2024 <\/strong>et du Nouveau-Brunswick \u00e0 compter du<strong> 24 juin 2024. <\/strong> <\/p>\n<p><span>Il s\u2019agit d\u2019une avanc\u00e9e importante pour les patients atteints de lupus en Saskatchewan, en Nouvelle-\u00c9cosse et au Nouveau-Brunswick, en leur offrant un meilleur acc\u00e8s aux traitements essentiels qui pourraient am\u00e9liorer leur qualit\u00e9 de vie et les aider \u00e0 g\u00e9rer leurs sympt\u00f4mes plus efficacement.<\/span><\/p>\n<p><strong>Inclusion dans le formulaire de la Saskatchewan :<\/strong> Le belimumab a \u00e9t\u00e9 inclus dans la prestation du statut de m\u00e9dicament d\u2019exception (EDS) de la Saskatchewan. Pour plus d\u2019informations, veuillez consulter les liens suivants :<\/p>\n<ul>\n<li><a rel=\"noreferrer noopener\" target=\"_new\" href=\"https:\/\/formulary.drugplan.ehealthsask.ca\/Bulletins\/Bulletin-0240-May-2024.pdf\">Bulletin sur le formulaire de la Saskatchewan &#8211; mai 2024<\/a><\/li>\n<li><a rel=\"noreferrer noopener\" target=\"_new\" href=\"https:\/\/formulary.drugplan.ehealthsask.ca\/SearchFormulary\/BG\/9332433\">Recherche de formulaires de la Saskatchewan<\/a><\/li>\n<\/ul>\n<p><strong>Inclusion dans le formulaire de la Nouvelle-\u00c9cosse :<\/strong> Le belimumab a \u00e9galement \u00e9t\u00e9 inclus dans la prestation du statut de nouveau m\u00e9dicament d\u2019exception du formulaire de la Nouvelle-\u00c9cosse. Pour plus d\u2019informations, veuillez consulter les liens suivants :<\/p>\n<ul>\n<li><a rel=\"noreferrer noopener\" target=\"_new\" href=\"https:\/\/novascotia.ca\/dhw\/pharmacare\/pharmacists_bulletins\/pharmacists-bulletin-24-07.pdf\">Bulletin sur l\u2019assurance-m\u00e9dicaments de la Nouvelle-\u00c9cosse &#8211; mai 2024<\/a><\/li>\n<li><a rel=\"noreferrer noopener\" target=\"_new\" href=\"https:\/\/novascotia.ca\/dhw\/pharmacare\/documents\/Criteria-for-Exception-Status-Coverage.pdf\">Crit\u00e8res de couverture du statut d\u2019exception<\/a><\/li>\n<\/ul>\n<p><strong>Formulaire des r\u00e9gimes d\u2019assurance-m\u00e9dicaments du Nouveau-Brunswick :<\/strong> Le b\u00e9limumab a \u00e9galement \u00e9t\u00e9 inclus dans le formulaire des R\u00e9gimes de m\u00e9dicaments du Nouveau-Brunswick \u00e0 compter du 24 juin 2024. Pour plus d\u2019informations, veuillez consulter les liens suivants :<\/p>\n<ul>\n<li><span style=\"font-size: 18px;\"><\/span><a href=\"https:\/\/www2.gnb.ca\/content\/dam\/gnb\/Departments\/h-s\/pdf\/en\/NBDrugPlan\/FormularyUpdates\/NBDrugPlansBulletin-1135.pdf\" target=\"_blank\" rel=\"noopener\">Mise \u00e0 jour sur le formulaire des R\u00e9gimes de m\u00e9dicaments du Nouveau-Brunswick<\/a><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><!-- \/divi:paragraph -->[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00a0\u00bb1&Prime; _builder_version=\u00a0\u00bb4.25.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb da_disable_devices=\u00a0\u00bboff|off|off\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb da_is_popup=\u00a0\u00bboff\u00a0\u00bb da_exit_intent=\u00a0\u00bboff\u00a0\u00bb da_has_close=\u00a0\u00bbon\u00a0\u00bb da_alt_close=\u00a0\u00bboff\u00a0\u00bb da_dark_close=\u00a0\u00bboff\u00a0\u00bb da_not_modal=\u00a0\u00bbon\u00a0\u00bb da_is_singular=\u00a0\u00bboff\u00a0\u00bb da_with_loader=\u00a0\u00bboff\u00a0\u00bb da_has_shadow=\u00a0\u00bbon\u00a0\u00bb][et_pb_row _builder_version=\u00a0\u00bb4.25.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.25.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_icon font_icon=\u00a0\u00bb&#xf1ea;||fa||400&Prime; icon_color=\u00a0\u00bb#6B198A\u00a0\u00bb icon_width=\u00a0\u00bb125px\u00a0\u00bb _builder_version=\u00a0\u00bb4.25.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_margin=\u00a0\u00bb-70px||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_icon][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nous sommes heureux d\u2019annoncer que le belimumab (Benlysta), un m\u00e9dicament d\u2019ordonnance utilis\u00e9 pour traiter les adultes atteints d\u2019inflammation r\u00e9nale li\u00e9e au lupus (n\u00e9phrite lupique active), a \u00e9t\u00e9 inclus dans la prestation du statut de drogue d\u2019exception (EDS) des listes de m\u00e9dicaments de la Saskatchewan et de la Nouvelle-\u00c9cosse \u00e0 compter du 1er mai 2024 et [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[92],"tags":[187,189,188,186,185],"topic":[114,116,113,119],"audience":[123,122,126,125,124],"class_list":["post-8888","post","type-post","status-publish","format-standard","hentry","category-article-fr","tag-lupus-fr","tag-produits-biologiques","tag-sante","tag-sante-canada","tag-traitements-du-lupus","topic-communaute-et-sensibilisation","topic-connaissances-medicales","topic-nouvelles-et-evenements","topic-plaidoyer-et-soutien","audience-j-ai-le-lupus","audience-j-ai-recemment-recu-un-diagnostic","audience-je-veux-plaider","audience-professionnel-de-la-sante","audience-une-personne-a-qui-je-tiens-a-le-lupus"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/posts\/8888","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/comments?post=8888"}],"version-history":[{"count":0,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/posts\/8888\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/media?parent=8888"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/categories?post=8888"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/tags?post=8888"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/topic?post=8888"},{"taxonomy":"audience","embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/audience?post=8888"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}